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Background and purpose   Prevention of osteonecrosis after cor-
ticosteroid administration would be important. We examined the 
potential of vitamin E (α-tocopherol) to reduce the incidence of 
corticosteroid-induced osteonecrosis in an animal model. 
Methods   Japanese white rabbits were divided into 2 groups; 
the control group was fed a normal diet and the experimental 
group was fed α-tocopherol-supplemented diet in which α-tocoph-
erol (600 mg/kg diet) was added to the normal diet. To induce 
osteonecrosis,  high-dose  methylprednisolone  acetate  (MPSL) 
(20 mg/kg body weight) was injected once into the right gluteus 
medius muscle of all rabbits. 4 weeks after the injection of MPSL, 
the presence or absence of osteonecrosis of bilateral femurs was 
examined  histopathologically. The  tocopherol/cholesterol  ratios 
were calculated. The plasma levels of thiobarbituric acid-reactive 
substances (TBARS) were measured.
Results   Alpha-tocopherol-supplemented diet reduced the inci-
dence of osteonecrosis, which developed in 14 of 20 rabbits in the 
control group and 5 of 21 rabbits in the experimental group (p = 
0.004). The tocopherol/cholesterol ratio was higher in the experi-
mental group than in the control group after the α-tocopherol 
administration. The plasma TBARS level was lower in the experi-
mental group than in the control group at 4 weeks after the MPSL 
administration.
Interpretation   Our findings may offer a new approach for the 
prevention of corticosteroid-induced osteonecrosis. 

Osteonecrosis of the hip occurs more frequently in patients 
who  receive  high-dose  corticosteroid  therapy  for  the  treat-
ment of diseases including systemic lupus erythematosus and 
inflammatory bowel disease, and also for immunosuppression 
after renal transplants (Spencer and Maisey 1985, Zizic et al. 
1985, Vakil and Sparberg 1989). When osteonecrosis involves 
a large volume of the femoral head, it collapses in many cases 
with  a  need  for  arthroplasty.  Since  corticosteroid-induced 
osteonecrosis of the hip tends to occur in relatively young 
patients, there is concern for the durability of prostheses with 
long-term use (Brinker et al. 1994, Chiu et al. 1997). 
There is consensus that one of the causal factors of osteo-
necrosis is the ischemic status inside the bone that forms after 
the administration of corticosteroid (Drescher et al. 2004). 
Various mechanisms have been proposed regarding the way 
in  which  corticosteroids  induce  osteonecrosis,  for  example 
hyperlipidemia, fat emboli, hypercoagulable condition, vas-
cular endothelial dysfunction, and apoptosis of bone tissues 
(Wang  et  al.  1977,  Jones  1985,  1992,  Kabata  et  al.  2000, 
Iuchi et al. 2003, Drescher et al. 2004). Even so, previous 
studies have been unable to clarify the detailed mechanism 
of the process by which corticosteroid administration induces 
the development of osteonecrosis. Recently, it was reported 
that using a rabbit model, oxidative injury was present in the 
bone shortly after corticosteroid administration and before the 
development of osteonecrosis (Ichiseki et al. 2005). Accord-
ingly,  we  believe  that  antioxidative  substances  may  allevi-
ate oxidative injury following corticosteroid administration, 
and  thus  prevent  osteonecrosis. Vitamin  E  is  a  fat-soluble 
substance in the body that has potent antioxidant properties 
(Burton et al. 1983). Various homologs of vitamin E exist in 
nature, and 8 substances including 4 types of tocopherols and 
4 types of tocotrienols have been identified. The biopotencies 
of tocopherols (relative to that of α-tocopherol, at 100) are 
30–50 for β-tocopherol, 10 for γ-tocopherol, and 2 or less for 
δ-tocopherol (Weiser and Vecchi 1982). The biopotencies of 
tocotrienols are known to be lower than tocopherols (Weiser 
and Vecchi 1982). Thus α-tocopherol, which has the highest 
potency of the known vitamin E homologs, should have the 
greatest potential for the prevention of osteonecrosis.
In this study, we examined the capacity of α-tocopherol to 
reduce the incidence of corticosteroid-induced osteonecrosis 
in an animal model. We also examined whether α-tocopherol 
could reduce the number of sites of osteonecrosis development 
in individual rabbits that developed osteonecrosis. Finally, we 
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orders of lipid metabolism, lipid peroxidation, and vascular 
damage after corticosteroid administration.
Material and methods
Animals and diets
All protocols in this study were followed in accordance with 
the guidelines of the Animal Care and Use Committee of our 
institution (date of issue: March 31, 2006; registration number: 
16-23).
Male Japanese white rabbits aged 28–32 weeks (Kitayama 
Labs Co. Ltd., Nagano, Japan) were kept in separate cages 
under controlled photoperiodic conditions comprising 12 h of 
light and 12 h of darkness at a temperature of 24 ± 1 °C. Their 
body weight was recorded on a weekly basis (baseline weight: 
3.3–3.9 kg). Water was provided by an automatic watering 
system. 50 rabbits were divided into two groups. Rabbits in the 
control group (n = 25) were fed with commercially available 
normal diet (ORC4; Oriental Yeast Co. Ltd., Tokyo, Japan), 
while those in the experimental group (n = 25) were fed with 
ORC4 diet supplemented with α-tocopherol, which contained 
600 mg α-tocopherol per kg. The ORC4 diet normally con-
tains 0.71 mg α-tocopherol per kg of diet. Alpha-tocopherol-
supplemented diet was prepared by the manufacturer (Oriental 
Yeast) by adding α-tocopherol at the ratio of 600 mg/kg diet to 
the ingredients of ORC4 during the manufacturing process.
A rabbit model of osteonecrosis
We used a rabbit model of corticosteroid-induced osteonecro-
sis (Yamamoto et al. 1997). 2 weeks after the start of feeding 
and after allocation of the rabbits into the 2 groups, a high 
dose of methylprednisolone acetate (MPSL) (20 mg/kg body 
weight;  Pfizer  Japan  Inc., Tokyo,  Japan)  was  administered 
once into the right gluteus medius muscle of all the rabbits to 
induce osteonecrosis. 
Tissue preparation 
4 weeks after administration of MPSL, the rabbits were killed 
with an excessive dose of intravenously injected sodium pen-
tobarbital. The bilateral femurs were immediately harvested 
and divided at the distal one-third and proximal one-third. The 
femurs were fixed in 10% buffered formalin for 1 week and 
then decalcified with 10% EDTA. After decalcification, the 
femurs were embedded in paraffin. 4-μm-thick coronal sec-
tions of the femurs were prepared and stained with hematoxy-
lin and eosin. 
Immunohistochemistry 
To examine the development of lipid peroxidation and vascular 
damage in bone, the femurs were stained immunohistochemi-
cally with anti-malondialdehyde monoclonal antibody (clone 
1F83) (Yamada et al. 2001). Briefly, after deparaffinization, the 
sections were treated with 3% H2O  2 for 10 min, rinsed in PBS 
(pH 7.6), and pretreated with 3% non-immune animal serum in 
PBS for 30 min at room temperature. Then the sections were 
reacted with monoclonal antibody to malondialdehyde (clone 
1F83) overnight at 4ºC. Sections were stained by the avidin-
biotin complex method. Sections were then treated with DAB, 
and counterstaining was carried out with hematoxylin. 
Evaluation of osteonecrosis
The presence or absence of osteonecrosis was determined in 
4 sections taken from the distal and proximal ends of both 
femurs of each rabbit. The sections were examined histopath-
ologically by two researchers who were kept blind regarding 
the identity of the treatment group. When the two examiners 
did not agree, they discussed the findings (still blind) to reach 
a consensus. A positive diagnosis of osteonecrosis was deter-
mined based on the diffuse presence of empty lacunae or pyk-
notic nuclei of osteocytes within the bone trabeculae, accom-
panied by surrounding bone marrow cell necrosis or fat cell 
necrosis (Yamamoto et al. 1997). Empty lacunae of osteocytes 
within the bone trabeculae without bone marrow cell necro-
sis or fat cell necrosis was not diagnosed as osteonecrosis. If 
osteonecrosis was found in at least 1 of the 4 sections, the 
rabbit was considered to have osteonecrosis. The number of 
rabbits that developed osteonecrosis, the source of the bone 
tissue, and the number of osteonecrosis sites that developed in 
each rabbit were recorded. 
Measurement of the size and area of fat cells in bone 
marrow
The effect of α-tocopherol on corticosteroid-induced adipo-
genesis was assessed by comparing the mean bone marrow fat 
cell size and the mean bone marrow fat cell area in the control 
group and in the experimental group. The effect of adipogene-
sis on osteonecrosis was also assessed by comparing the mean 
fat cell size and the mean fat cell area in the rabbits that devel-
oped osteonecrosis (the ON+ group) and in the rabbits that did 
not develop osteonecrosis (the ON- group). The bone marrow 
fat cell size was calculated as an average of the greatest diame-
ters of 100 fat cells in 4 randomly-selected non-necrotic fields 
(one field = 25 × 10-8 m2) from the proximal one-third of the 
femur using image analysis software (ImageJ version 1.41o; 
National Institutes of Health, MD) (Parfitt et al. 1987, Pengde 
et al. 2008). The fat cell area, including the necrotic area of the 
marrow fat cells, and the trabecular bone within the femoral 
head proximal to a straight line connecting the edges of the 
articular cartilage (6 sections from each rabbit) was quanti-
tated histomorphometrically with the Mocha program based 
on the method suggested by the American Society of Bone and 
Mineral Research Histomorphometry Nomenclature Commit-
tee (Parfitt et al. 1987, Pengde et al. 2008). 
Evaluation of lipid peroxidation and vascular damage 
in bone
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peroxidation and vascular damage was assessed by compar-
ing immunohistological data in the control group and in the 
experimental group. The effect of corticosteroid-induced lipid 
peroxidation and vascular damage on osteonecrosis was also 
assessed by comparing immunohistological data between the 
ON+ group and the ON- group. The anti-malondialdehyde 
antibody-positive (MDA+) marrow vessels were counted in 
4 randomly-selected fields from the proximal one-third of the 
femur (one field = 25 × 10-8 m2).
Estimation of α-tocopherol intake 
The food intake of a rabbit was calculated by subtracting the 
weight of the remaining food in the hopper from the weight 
of the food supplied. The intake of α-tocopherol (mg/kg/day) 
was calculated based on these values. 
Hematological examination
Blood  samples  were  collected  in  the  morning,  from  the 
auricular  artery  of  each  rabbit  in  a  fasting  state.  Samples 
were collected at the start of the study (week –2), immedi-
ately before the administration of MPSL (week 0), 2 weeks 
after the administration of MPSL (week 2), and 4 weeks after 
the administration (week 4). Heparin was added to the blood 
samples and they were centrifuged at 3,000 rpm for 15 min at 
4ºC. The supernatant was stored under light-shielded condi-
tions at –80ºC. The plasma levels of tocopherol (mg/dL) were 
measured by the fluorescence method (Thompson et al. 1973) 
(Mitsubishi Chemical Medience Corporation, Tokyo, Japan). 
The plasma levels of total cholesterol (T-cho; mg/dL) and tri-
glycerides (TG; mg/dL) were measured using an automated 
analyzer. The extent of lipid peroxidation was determined as 
thiobarbituric acid-reactive substances (TBARS) in plasma. 
The plasma levels of TBARS (μM) were measured using the 
Malondialdehyde Assay kit (NWK-MD01; Northwest, Van-
couver, WA). The measurement principle of TBARS is as fol-
lows: malondialdehyde (MDA) in plasma reacts with thiobar-
bituric acid (TBA) and forms MDA-TBA2, which has strong 
absorbance at a wavelength of 532 nm. The level of MDA-
TBA2 is quantified by spectrophotometry. Plasma tocopherol 
concentrations are known to be dependent on total cholesterol 
concentration (Vatassery et al. 1983). Thus, the tocopherol/
cholesterol ratios were calculated.
Statistics
Categorical data, i.e. incidence of osteonecrosis, was analyzed 
using Fisher’s exact probability test. Numerical data in each 
group were expressed as means and standard deviation (SDs). 
Simple comparisons of numerical data were performed using 
Student’s t-test. Longitudinal numerical data, i.e. hematologi-
cal data, at 4 time points (week –2, week 0, week 2, and week 
4) were expressed as means and SDs and were analyzed using 
the Tukey-Kramer method for all pairwise comparisons with 
α set a priori to 0.05. Statistical analyses were performed 
using Excel 2007 (Microsoft) with the add-on software Stat-
cel 2 (Yanai H, 2004) and with p-values of < 0.05 considered 
statistically significant.
 
Results
Incidence of osteonecrosis
9 of the 50 rabbits died after the administration of MPSL and 
were excluded from the evaluation. 5 were in the control group 
and 4 were in the experimental group. 14 of the 20 rabbits in 
the control group and 5 of the 21 rabbits in the experimental 
group developed osteonecrosis (Figure 1). The α-tocopherol-
supplemented diet reduced the incidence of osteonecrosis (p = 
0.004, Fisher’s exact probability test). There was no difference 
in the number of osteonecrosis sites in each rabbit that devel-
oped osteonecrosis between the two groups (control group: 
1.57 (SD 0.65); experimental group: 1.80 (SD 0.45); p = 0.5).
Size and area of bone marrow fat cells
The diameter of fat cells was 54 (SD 7.0) μm in the control 
group and 56 (SD 3.7) μm in the experimental group (p = 
0.3). The diameter of fat cells was 54 (SD 4.3) μm in the ON+ 
group and 55 (SD 6.7) μm in the ON- group (p = 0.5). The area 
of fat cells was 57% (SD 6.6) in the control group, and 57% 
(SD 6.8) in the experimental group (p = 0.9). The area of fat 
cells was 57% (SD 6.5) in the ON+ group and 56% (SD 7.0) 
in the ON- group (p = 0.7). 
Lipid peroxidation and vascular damage in bone
By  immunostaining  with  anti-malondialdehyde  antibody 
(clone 1F83), vessels in the bone marrow and bone marrow 
cells were stained brown (Figure 2). The number of MDA+ 
vessels was 3.9 (SD 2.3) in the control group, and 1.4 (SD 
0.96) in the experimental group (p < 0.001). The MDA+ vessel 
counts were 3.9 (SD 2.1) in the ON+ group, and 1.5 (SD 1.4) 
in the ON- group (p = 0.001). 
Intake of α-tocopherol
The intake of food during the experimental period was 4,987 
(SD 542) g in the control group, and 4,981 (SD 541) g in the 
experimental group (NS). The intake of α-tocopherol was 0.02 
(SD 0.01) mg/kg/day in the control group and 20.3 (SD 5.9) 
mg/kg/day in the experimental group (p < 0.001). 
Hematological findings
Hematological data for the control group and the experimental 
group were compared at the same time points (between-group 
comparison), and between week 2 (baseline) and the 3 other 
time points in the group (within-group comparison) (Figure 
3).  The  tocopherol/cholesterol  ratios  in  the  experimental 
group increased during the period from week 0 to week 4 (p 
< 0.01). Regarding plasma levels of total cholesterol (T-cho) 
and triglycerides (TG), there was no difference between the 
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experimental group at week 2 and that in the control group 
at week 4 were higher than the baseline level (p < 0.01). The 
plasma levels of TG increased during the period from week 
2 to week 4 in both groups (p < 0.01). Hemolysis and lipe-
mia were considered to lead to measurement errors of plasma 
TBARS levels for the following reasons. Hemoglobin, which 
is released by hemolysis (the collapse of red blood cells) has an 
absorbance peak around the same wavelength as that of MDA-
TBA2, which affects the TBARS value measured by spectro-
photometry. Also, lipemia, which means high levels of lipids 
in plasma, affects measurement values by spectrophotometry 
by  raising  background  levels.  Thus,  we  excluded  samples 
with high levels of hemolysis and lipemia, considering that 
we could not overlook the potential error caused by the effect 
of these on TBARS level—the index of lipid peroxidation for 
which precision is especially required in our study design. 
All samples obtained 2 weeks after the MPSL administration 
(except 1 plasma sample in the control group) were severely 
lipemic and were thus excluded from the statistical analysis. 
The plasma TBARS level at week 4 in the experimental group 
was lower than that in the control group (p < 0.01). 
Discussion
Alpha-tocopherol statistically significantly reduced the inci-
dence of osteonecrosis in this rabbit model of corticosteroid-
induced osteonecrosis. This finding suggests that the intake of 
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Figure 1. Histological features of osteonecrosis in rabbits. A. Nomal bone harvested from a comparable rabbit not treated with α-tocopherol nor 
treated with methylprednisolone acetate. B. Typical osteonecrotic lesion (experimental group). C. Nomal bone marrow cells. D. Necrotic bone 
marrow cells. Bone marrow cells had necrosis and stained acidophilic. The nuclei of bone marrow cells displayed pyknosis and karyorrhexis. The 
cellular structure of fat cells collapsed. E. Normal bone. Empty lacunae of the osteocytes (arrowhead) without bone marrow cell necrosis or fat cell 
necrosis. F. Osteonecrotic bone. Bone cells in the bone trabeculae showed pyknosis and empty lacunae (arrow) that were associated with necrotic 
changes of the surrounding bone marrow cells. Stain: hematoxylin and eosin; magnification: ×200 (A, B), ×400 (C, D, E, F).
  B   A
Figure 2. A. Strong immunoreactivity found 
in both a marrow vessel and bone marrow 
cells.  B.  Weak  immunoreactivity  found  in 
both  a  marrow  vessel  and  bone  marrow 
cells.  Stain:  anti-malondialdehyde  mono-
clonal antibody (clone 1F83); magnification: 
×200.158  Acta Orthopaedica 2010; 81 (1): 154–160
α-tocopherol may prevent corticosteroid-induced osteonecro-
sis. However, there were still rabbits that developed osteone-
crosis. Alpha-tocopherol did not reduce the number of sites of 
osteonecrosis development in individual rabbits that developed 
osteonecrosis. We found no influence of α-tocopherol on the 
severity of osteonecrosis. The results indicate that the cause 
of osteonecrosis is multifactorial (Wang et al. 1977, Jones 
1985, 1992, Kabata et al. 2000, Iuchi et al. 2003, Drescher 
et al. 2004, Zhang et al. 2009). There may be a threshold in 
the development of osteonecrosis, which, once reached, may 
mean  the  initiation  of  development  of  osteonecrosis  even 
though prophylactic treatment is given.
We evaluated disorders of lipid metabolism by measuring 
T-cho and TG with a biochemical approach, as well as fat cell 
size and area by histology. T-cho and TG levels increased after 
the administration of MPSL to a similar extent in the experi-
mental group and the control group. Regarding the size and 
area of fat cells, no statistically significant differences were 
found between the experimental group and the control group 
and  between  the  ON+  and  ON-  groups.  Other  researchers 
reported that disorders of lipid metabolism was osteonecro-
sis-prevention mechanism (Motomura et al. 2004, Pengde et 
al. 2008, Zhang et al. 2009). Disorders of lipid metabolism 
was not improved by α-tocopherol. These results indicate that 
some other osteonecrosis-prevention mechanisms exist other 
than disorders of lipid metabolism.
We  also  evaluated  vascular  damage  caused  by  oxidative 
stress by measuring TBARS with a biochemical approach and 
by counting the number of MDA+ vessels using a histological 
approach. The TBARS level and the number of MDA+ ves-
sels were lower in the experimental group than in the control 
group. Alpha-tocopherol reduced oxidative stress in the blood 
and in the blood vessels. Vascular endothelial cells that are 
constantly exposed to blood flow are susceptible to injury by 
oxidative stress (Schilling and Elliott 1992). When they are 
subjected to oxidative stress, the production of nitric monox-
ide (NO), which is an endothelium-derived vascular relaxation 
factor, becomes reduced (Niu et al. 1994). Since NO has an 
anti-platelet  effect  through  elevation  of  cyclic  GMP  levels 
in the platelets, oxidative stress suppresses this anti-platelet 
effect from the reduction of NO production. Also, vascular 
endothelial damage due to oxidative stress reduces thrombo-
modulin production. When the coagulation system is activated 
locally, thrombin is produced but immediately inactivated by 
binding with thrombomodulin on vascular endothelial cells. 
Also, the complex of thrombin and thrombomodulin activates 
the protein C-dependent anticoagulant pathway. In short, vas-
cular endothelial damage by oxidative stress  the anticoagu-
Figure 3. Hematological findings. The tocopherol/cholesterol ratios (A), total cholesterol levels (B), triglyceride levels 
(C), and concentration of thiobarbituric acid-reactive substances (D) are shown. a P < 0.05, b P < 0.01 by Tukey-Kramer 
method for between-group and within-group comparisons).
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lation  system  through  reduced  thrombomodulin  production 
(Lentz et al. 1999). Thus, we believe that α-tocopherol sup-
pressed vascular damage by reducing oxidative stress in the 
blood and blood vessels, thereby maintaining anti-platelet and 
anticoagulant effects. We infer that this is one of the mecha-
nisms by which α-tocopherol prevents the development of ste-
roid-induced osteonecrosis. 
Various hypotheses have been put forward for the etiologi-
cal factors involved in corticosteroid-induced osteonecrosis, 
including disorders of lipid metabolism and abnormalities in 
the coagulation and fibrinolytic system (Wang et al. 1977, Jones 
1985, 1992, Drescher et al. 2004). Based on these hypotheses, 
several animal studies have been done in an attempt to estab-
lish methods to prevent corticosteroid-induced osteonecrosis. 
It has been reported that single or combined administration 
of probucol (a lipid-lowering agent) and/or warfarin (an anti-
coagulant) is effective in the prevention of osteonecrosis in 
rabbits (Motomura et al. 2004). It has also been reported that 
pravastatin  and  simvastatin  treatments  have  a  preventative 
effect against osteonecrosis in rabbits but that this is not the 
case with probucol treatment, and that all three agents suppress 
elevation of lipid levels (Iwakiri et al. 2008). Also, icaritin has 
been reported to exert a dose-dependent effect on reducing 
the incidence of osteonecrosis with inhibition of intravascu-
lar thrombosis and extravascular lipid deposition (Zhang et al. 
2009). From these reports, it is likely that there exist multiple 
mechanisms for the suppression of osteonecrosis in addition 
to the reduction of lipid levels (Motomura et al. 2004, Iwa-
kiri et al. 2008, Zhang et al. 2009). Other pathophysiological 
events may also play an important role in the development 
of osteonecrosis, such as the corticosteroid-induced hyperco-
agulable condition and genetic predisposition, which can lead 
to intravascular coagulation and microcirculatory disturbance 
(Zhang et al. 2009). Our hypothesis is supported by the report 
by Zhang et al. 
Many biochemical and biological studies have been done 
using α-tocopherol, and its antioxidant, membrane stabiliz-
ing, and microcirculation activation effects have been reported 
(Burton et al. 1983, Tasinato et al. 1995). Our hypothesis is 
supported by the results of one study in which oxidative injury 
occurred  after  corticosteroid  administration  but  before  the 
development of osteonecrosis, and by another study show-
ing that glutathione, which is also an antioxidant, suppressed 
osteonecrosis (Ichiseki et al. 2004, 2005). 
It has been reported that α-tocopherol is a safe agent and that 
its upper limit of no observed adverse effect level (NOAEL) 
in humans when used as a medicine is 1,600 mg/day (Kappus 
and Diplock 1992). The amount of α-tocopherol that each 
rabbit consumed in this study was equivalent to about 1,2 mg/
day for a man (60 kg). 
Our study has the following limitations. Because the occur-
rence of osteonecrosis was evaluated at only one time point, 
4 weeks after the MPSL administration, it is possible that 
osteonecrosis had been repaired before this time point or that 
the development of osteonecrosis was delayed. Because we 
limited the intake of α-tocopherol to 600 mg/kg diet, we were 
unable to determine the optimum level of α-tocopherol that 
can suppress the development of osteonecrosis. Thus, future 
studies should determine the timing of osteonecrosis develop-
ment and the level of α-tocopherol required to elicit this sup-
pressive effect on the development.
In this study, α-tocopherol was administered orally to rab-
bits (in their food) at a safe dose and it suppressed corticoste-
roid-induced osteonecrosis. Since α-tocopherol is safe and is 
frequently used in clinical settings, we believe that this agent 
could easily be tested in clinical trials to confirm its effect on 
prevention of osteonecrosis in humans, although further stud-
ies are required before that.
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